[1] Li ZZ, Xue J, Chen P,et al. Prevalence of nonalcoholic fatty liver disease in mainland of China: A meta-analysis of published studies. J GastroenterolHepatol, 2014, 29(1):Z42-251. [2] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic Fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64(1):73-84. [3] Cengiz M, Sentürk S, Cetin B, et al. Sonographic assessment of fatty liver: intraobserver and interobserver variability. Int J Clin Exp Med, 2014, 7(12):5453. [4] Wong LH. Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol, 2014, 20(3): 228-236. [5] Ou XJ, Wang XM, Wu XN, et al. Comparison of FibroTouch and FibroScan for the assessment of fibrosis in chronic hepatitis B patients. Chin J Hepatol, 2015, 23(2): 103-106. [6] Deng H, Wang C, Lai J, et al. Noninvasive diagnosis of hepatic steatosis using fat attenuation parameter measured by FibroTouch and a new algorithm in CHB patients. Hepat Mon,2016, 16(9):e40263. [7] Lei J, Ji X, Hong J, et al. Prediction of posthepatectomy liver failure using transient elastography in patients with hepatitis B related hepatocellular carcinoma. BMC Gastroenterol, 2017, 17: 171. [8] Xu Y, Liu Y, Cao Z, et al. Comparison of FibroTouch and FibroScan for staging fibrosis in chronic liver disease: single-center prospective study. Dig Liver Dis, 2019, 51(9):1323-1329. [9] Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis. Hepatology, 2019, 70:1119-1133. [10] Cai W, Song J, Zhang B, et al. The prevalence of nonalcoholic fatty liver disease and relationship with serum uric acid level in Uyghur population. Sci World J, 2014, 23(6):393628. [11] 管红雨,蔡晓波,陆伦根.缺氧对非酒精性脂肪性肝病发病的影响.实用肝脏病杂志,2016, 19(2):237-240. [12] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会. 非酒精性脂肪性肝病防治指南(2018 年版). 实用肝脏病杂志,2018,21(2):177-186. [13] 李静波,刘姝,温博,等.FibroTouch与超声、CT对NAFLD的诊断价值比较.临床肝胆病杂志,2016,34(3): 459-462. [14] 温博,王炳元,李静波,等.Fibrotouch与超声诊断NAFLD一致性分析.中国肝脏病杂志(电子版),2016,8(2):19-23. [15] Stern C, Castera L. Non-invasive diagnosis of hepatic steatosis. Hepatol Int, 2017,11: 70-78. [16] Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol,2013, 10:666-675. [17] Marshall RH, Eissa M, Bluth EI, et al. Hepatorenal index as an accurate, simple, and effective tool in screening for steatosis. Am J Roentgenol, 2012, 199(5): 997-1002. [18] Shen L1, Li JQ, Zeng MD,et al. Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. World J Gastroenterol, 2006, 12(8): 1292-1295. [19] Tada T,Kumada T,Toyoda H,et al. Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease. Hepatol Commun,2017,1(9):899-910. [20] Andrade P, Rodrigues S, Rodrigues-Pinto E, et al. Diagnostic accuracy of controlled attenuation parameter for detecting hepatic steatosis in patients with chronic liver disease. GE Port J Gastroenterol, 2017, 24(4):161-168. [21] Kaya E,Demir D,Alahdab YO,et al. Prevalence of hepaticsteatosis in apparently healthy medical students:a transient elastography study on the basis of a controlled attenuation parameter. Eur J Gastroenterol Hepatol, 2016, 28(11): 1264-1267. |